Reviewed by Peptide Treatments Medical Advisory Board
CagriSema: Evidence Summary
Evidence summary for CagriSema across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to CagriSema overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Chronic weight management | Tier A | 6 | Phase 3 COMPASS program — 22-25% weight loss in 7,000+ subjects |
| Type 2 diabetes with obesity | Tier B | 2 | 18.4% weight loss in T2D population (COMPASS-2) |
| Cardiovascular risk reduction | Tier D | 1 | CVOT ongoing — no outcomes data yet |
References (4)
- CagriSema Phase 3 COMPASS-1 Trial: Weight Loss Efficacy — Novo Nordisk . New England Journal of Medicine (2025) NCT05654351
- CagriSema Phase 3 COMPASS-2 Trial: Obesity with T2D — Novo Nordisk . Lancet (2025) NCT05654364
- CagriSema Phase 2 REDEEM-1: Dose-Ranging Study — Multiple authors . Lancet (2024)
- CagriSema Phase 2 REDEEM-2: Obesity with T2D — Multiple authors . Diabetes Care (2024)